Gilead Sciences: ‘HIV Succession Plan Coming Into Focus’

Nomura’s M. Ian Somaiya believes Gilead Sciences’ (GILD) “HIV succession plan [is] coming into focus.” He explains: Sipa USA/Associated Press We reiterate our Buy rating and $141 TP on Gilead following presentation of multiple TAF trials at the ongoing CROI meeting. In the trials, TAF-based Quad was non-inferior to Stribild in treatment naïve adult patients, while also [...]